The IC50 value for PXL-4720 was approximately 100-fold lower (range: 17.5 to 280 nM) than sorafenib in melanomas and colon carcinomas that had the BRAF V600E mutation; however, the IC50 value for PLX-4720 was approximately the same as sorafenib in colon carcinomas and NSCLC without BRAF mutations, but with RAS mutations. Here, BRAF is linked to non-small cell lung carcinoma.